Phreesia Reports Q4 Earnings Miss Amid Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Source: Benzinga
Phreesia Inc's stock fell 27.78% as it crossed below the 5-day SMA, reflecting investor concerns following its Q4 earnings report.
The company reported a Q4 GAAP EPS of $0.02, missing expectations by $0.04, which raises potential challenges in profitability that may affect investor confidence. Despite achieving a revenue of $127.07 million, a 15.9% year-over-year increase, the earnings miss could pressure the stock price in the short term. Additionally, Phreesia projected FY revenue of $510-520 million, below the IBES estimate of $552 million, indicating market uncertainty.
Investors are likely to monitor Phreesia's strategies for improving profitability and optimizing its cost structure to enhance its competitive position in the healthcare technology sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHR
Wall Street analysts forecast PHR stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.660
Low
24.00
Averages
29.09
High
35.00
Current: 10.660
Low
24.00
Averages
29.09
High
35.00
About PHR
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Phreesia Faces Class Action Lawsuit Amid Revenue Downgrade
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Phreesia, alleging securities fraud and other unlawful business practices, with investors needing to apply as Lead Plaintiff by July 13, 2026.
- Revenue Guidance Downgrade: On March 30, 2026, Phreesia significantly reduced its revenue growth projections for fiscal year 2027, citing macroeconomic factors such as worsening visibility and weaker pharmaceutical marketing commitments affecting its Network Solutions segment.
- Stock Price Plunge: Following the revenue downgrade, Phreesia's stock price fell by $3.03, or 26.56%, closing at $8.38 per share on March 31, 2026, indicating market pessimism regarding the company's future outlook.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in class action litigation, with a long history of recovering multimillion-dollar damages for victims of securities fraud, showcasing its expertise in handling complex securities cases.
See More
Phreesia Investors Class Action Reminder
- Lawsuit Background: On March 30, 2026, Phreesia announced significantly lowered revenue growth projections for fiscal 2027, resulting in a 26.6% drop in stock price to $8.38 per share the following day, causing substantial losses for investors.
- False Information Allegations: The complaint alleges that throughout the class period, the company misled investors by projecting confidence in its long-term growth outlook while downplaying risks associated with slowing growth in its Network Solutions segment.
- Class Action Deadline: Investors must file a lead plaintiff motion by July 13, 2026, to seek compensation for losses incurred during the class period, emphasizing the urgency for affected shareholders to act.
- Legal Consultation Information: Glancy Prongay Wolke & Rotter LLP offers legal consultation, encouraging investors to reach out via email or phone for further information to ensure their rights are protected.
See More
Reminder of Phreesia Stock Class Action Lawsuit
- Class Action Notification: Rosen Law Firm reminds investors who purchased Phreesia (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026, to apply as lead plaintiffs by July 13, 2026, or risk not being represented in the class action lawsuit.
- Fee Arrangement: Participants can receive compensation without any upfront costs through a contingency fee arrangement, which alleviates the financial burden on investors and encourages more affected shareholders to join the lawsuit.
- Lawsuit Background: The lawsuit alleges that Phreesia made false and misleading statements during the class period, concealing adverse facts such as weakened pharmaceutical marketing commitments in its Network Solutions segment, leading to investor losses when the truth emerged.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked first in 2017 for the number of settlements, demonstrating its expertise and success in this legal domain.
See More
Phreesia Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Phreesia in the U.S. District Court for Delaware on behalf of investors who purchased shares between May 8, 2025, and March 30, 2026, highlighting significant concerns regarding the company's financial transparency.
- Allegation Details: The complaint alleges that Phreesia and its executives violated federal securities laws by failing to disclose the true state of slowing demand and reduced visibility in key revenue streams, particularly the weakened pharmaceutical marketing commitments in its Network Solutions segment, potentially leading to investor losses.
- Revenue Guidance Downgrade: In its Q4 2026 earnings release, Phreesia lowered its fiscal 2027 revenue guidance to $510 million to $520 million, down from $545 million to $559 million, reflecting the market challenges the company is facing.
- Stock Price Impact: Following the revenue guidance downgrade, Phreesia's stock price fell by 21% to 28%, indicating market concerns about the company's future performance, prompting investors to stay informed about their legal rights.
See More
Reminder of Shareholder Class Action Lawsuits
- Lawsuit Overview: Holzer & Holzer, LLC reminds investors of a class action lawsuit against Graphic Packaging Holding Company, alleging that the company failed to disclose critical inventory management information between February 2025 and February 2026, resulting in investor losses.
- Key Deadlines: Investors must apply to be appointed lead plaintiff by July 6, 2026, to protect their legal rights, with similar lawsuits also filed against Immutep Limited and Phreesia, Inc.
- Legal Consultation Access: Affected investors are encouraged to contact Holzer & Holzer through their website or toll-free number to learn more about their legal rights and ensure timely action.
- Law Firm Credentials: Holzer & Holzer, LLC is a top-rated securities litigation law firm recognized for its vigorous representation of shareholders, having recovered hundreds of millions of dollars for defrauded investors since its inception in 2000, showcasing its expertise in protecting investor interests.
See More
Phreesia Faces Securities Class Action Lawsuit
- Significant Stock Decline: Phreesia's shares fell approximately 27% on March 31, 2026, losing $3.03 per share to close at $8.38, primarily due to the company's downward revision of its fiscal 2027 revenue outlook from $545-$559 million to $510-$520 million, which directly impacts investor confidence and market performance.
- Class Action Initiation: The securities class action against Phreesia and certain executives alleges that they disseminated materially misleading statements regarding fiscal 2027 revenue growth prospects while concealing deteriorating pharmaceutical marketing commitments in the Network Solutions segment, potentially exposing investors to legal liabilities and financial losses.
- Investor Obligations: Institutional investors holding PHR securities must evaluate potential recovery options for losses, as failing to do so may raise questions about their fiduciary duties, especially in the context of alleged securities fraud, necessitating active participation in the litigation to protect their interests.
- Lead Plaintiff Opportunities: Institutional investors can apply to become lead plaintiffs, allowing them direct oversight of litigation strategy and settlement terms without incurring out-of-pocket costs, as attorney fees will be paid from any recovery, ensuring their proactive role and maximization of interests in the legal process.
See More
Phreesia Faces Class Action Lawsuit Amid Revenue Downgrade
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Phreesia, alleging securities fraud and other unlawful business practices, with investors needing to apply as Lead Plaintiff by July 13, 2026.
- Revenue Guidance Downgrade: On March 30, 2026, Phreesia significantly reduced its revenue growth projections for fiscal year 2027, citing macroeconomic factors such as worsening visibility and weaker pharmaceutical marketing commitments affecting its Network Solutions segment.
- Stock Price Plunge: Following the revenue downgrade, Phreesia's stock price fell by $3.03, or 26.56%, closing at $8.38 per share on March 31, 2026, indicating market pessimism regarding the company's future outlook.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in class action litigation, with a long history of recovering multimillion-dollar damages for victims of securities fraud, showcasing its expertise in handling complex securities cases.
See More
Phreesia Investors Class Action Reminder
- Lawsuit Background: On March 30, 2026, Phreesia announced significantly lowered revenue growth projections for fiscal 2027, resulting in a 26.6% drop in stock price to $8.38 per share the following day, causing substantial losses for investors.
- False Information Allegations: The complaint alleges that throughout the class period, the company misled investors by projecting confidence in its long-term growth outlook while downplaying risks associated with slowing growth in its Network Solutions segment.
- Class Action Deadline: Investors must file a lead plaintiff motion by July 13, 2026, to seek compensation for losses incurred during the class period, emphasizing the urgency for affected shareholders to act.
- Legal Consultation Information: Glancy Prongay Wolke & Rotter LLP offers legal consultation, encouraging investors to reach out via email or phone for further information to ensure their rights are protected.
See More
Reminder of Phreesia Stock Class Action Lawsuit
- Class Action Notification: Rosen Law Firm reminds investors who purchased Phreesia (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026, to apply as lead plaintiffs by July 13, 2026, or risk not being represented in the class action lawsuit.
- Fee Arrangement: Participants can receive compensation without any upfront costs through a contingency fee arrangement, which alleviates the financial burden on investors and encourages more affected shareholders to join the lawsuit.
- Lawsuit Background: The lawsuit alleges that Phreesia made false and misleading statements during the class period, concealing adverse facts such as weakened pharmaceutical marketing commitments in its Network Solutions segment, leading to investor losses when the truth emerged.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked first in 2017 for the number of settlements, demonstrating its expertise and success in this legal domain.
See More
Phreesia Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Phreesia in the U.S. District Court for Delaware on behalf of investors who purchased shares between May 8, 2025, and March 30, 2026, highlighting significant concerns regarding the company's financial transparency.
- Allegation Details: The complaint alleges that Phreesia and its executives violated federal securities laws by failing to disclose the true state of slowing demand and reduced visibility in key revenue streams, particularly the weakened pharmaceutical marketing commitments in its Network Solutions segment, potentially leading to investor losses.
- Revenue Guidance Downgrade: In its Q4 2026 earnings release, Phreesia lowered its fiscal 2027 revenue guidance to $510 million to $520 million, down from $545 million to $559 million, reflecting the market challenges the company is facing.
- Stock Price Impact: Following the revenue guidance downgrade, Phreesia's stock price fell by 21% to 28%, indicating market concerns about the company's future performance, prompting investors to stay informed about their legal rights.
See More
Reminder of Shareholder Class Action Lawsuits
- Lawsuit Overview: Holzer & Holzer, LLC reminds investors of a class action lawsuit against Graphic Packaging Holding Company, alleging that the company failed to disclose critical inventory management information between February 2025 and February 2026, resulting in investor losses.
- Key Deadlines: Investors must apply to be appointed lead plaintiff by July 6, 2026, to protect their legal rights, with similar lawsuits also filed against Immutep Limited and Phreesia, Inc.
- Legal Consultation Access: Affected investors are encouraged to contact Holzer & Holzer through their website or toll-free number to learn more about their legal rights and ensure timely action.
- Law Firm Credentials: Holzer & Holzer, LLC is a top-rated securities litigation law firm recognized for its vigorous representation of shareholders, having recovered hundreds of millions of dollars for defrauded investors since its inception in 2000, showcasing its expertise in protecting investor interests.
See More
Phreesia Faces Securities Class Action Lawsuit
- Significant Stock Decline: Phreesia's shares fell approximately 27% on March 31, 2026, losing $3.03 per share to close at $8.38, primarily due to the company's downward revision of its fiscal 2027 revenue outlook from $545-$559 million to $510-$520 million, which directly impacts investor confidence and market performance.
- Class Action Initiation: The securities class action against Phreesia and certain executives alleges that they disseminated materially misleading statements regarding fiscal 2027 revenue growth prospects while concealing deteriorating pharmaceutical marketing commitments in the Network Solutions segment, potentially exposing investors to legal liabilities and financial losses.
- Investor Obligations: Institutional investors holding PHR securities must evaluate potential recovery options for losses, as failing to do so may raise questions about their fiduciary duties, especially in the context of alleged securities fraud, necessitating active participation in the litigation to protect their interests.
- Lead Plaintiff Opportunities: Institutional investors can apply to become lead plaintiffs, allowing them direct oversight of litigation strategy and settlement terms without incurring out-of-pocket costs, as attorney fees will be paid from any recovery, ensuring their proactive role and maximization of interests in the legal process.
See More
